Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Accumulated Expenses: 2022-2023

  • Day One Biopharmaceuticals' Other Accumulated Expenses rose 481.56% to $1.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.0 million, marking a year-over-year increase of 481.56%. This contributed to the annual value of $1.0 million for FY2023, which is 481.56% up from last year.
  • According to the latest figures from Q4 2023, Day One Biopharmaceuticals' Other Accumulated Expenses is $1.0 million, which was up 481.56% from $179,000 recorded in Q4 2022.
  • In the past 5 years, Day One Biopharmaceuticals' Other Accumulated Expenses registered a high of $1.0 million during Q4 2023, and its lowest value of $179,000 during Q4 2022.
  • Moreover, its 2-year median value for Other Accumulated Expenses was $610,000 (2022), whereas its average is $610,000.
  • Data for Day One Biopharmaceuticals' Other Accumulated Expenses shows a peak YoY spiked of 481.56% (in 2023) over the last 5 years.
  • Quarterly analysis of 2 years shows Day One Biopharmaceuticals' Other Accumulated Expenses stood at $179,000 in 2022, then surged by 481.56% to $1.0 million in 2023.